Delta-8 THC is an analog of tetrahydrocannabinol (THC) with antiemetic, anxiolytic, appetite-stimulating, and analgesic effects. Delta 8 flower has a local anesthetic activity similar to that of procaine, although much less potent.
Delta-8 THC acts as a highly selective agonist at the cannabinoid receptor CB1, with a very low affinity for CB2. It was originally patented by William Anthony Devane in 1982 while working at Sterling-Winthrop pharmaceuticals. The patent claims were filed on January 18, 1980, and granted on July 27, 1988 (US Patent 4646957). A later study showed that the dextrorotatory enantiomer of delta 8 THC was more potent than the levorotatory enantiomer and that racemic delta 8 THC while providing analgesic effects, would also cause dysphoric reactions due to its psychoactive effects.
Delta-8 THC is one of four stereoisomers of tetrahydrocannabinol (THC), the other three being THCA, CBDA and CBCA. It has been shown by X-ray crystallography analysis at 2.05 Å resolution. Studies have been done to determine how synthetic cannabinoids such as JWH-018 bind specifically to the CB1 receptor as an agonist with minimal activity towards CB2. In a study done in 2009, it was found that two hydrogen bonds were responsible for recognizing the aromatic portion of cannabinoid receptor 1 (CB1). Buy Delta 8 THC Flower Online, and it will be delivered to your home.
A combination of three hydrogen bonds and Van der Waals interactions were needed to bind anandamide, also an agonist at CB1. When compared with the average synthetic cannabinoid binding in this way it was found that JWH-018 had a difference in an activity that can be attributed to the lack of these hydrogen bonds and Van der Waals interactions. This finding is backed up by another study done with AM6527 which showed no significant SR-144302 like properties when tested at CB1. It’s important to note that most cannabinoids such as THC and synthetic cannabinoids anandamide have both SR-144302 like and JWH-018 like properties so it makes sense for them to share a structure although they function quite differently.
Delta-8 THC has local anesthetic activity similar to that of procaine, although much less potent. Delta-8 THC is an agonist at CB1 and CB2 receptors with low nanomolar affinity for both. The receptor subtype selectivity was determined by evaluating the inhibition constant (Ki) values at the cannabinoid receptors using human embryonic kidney cell line expressing cDNA corresponding to CB1 or CB2 receptors. The Highest Ki value was observed at the CB2 receptor. By applying structure-activity relationship, it can be concluded that modification on C8 position is more suitable than on C7, which is planar in delta-8 THCs. It should be noted that neither enantiomers nor diastereomeric derivatives of this compound have been tested at the CB1 and CB2 receptors to determine whether they might show even higher affinities.
Delta-8 THC acts as a highly selective agonist at the cannabinoid receptor CB1, with a very low affinity for CB2. It was originally patented by William Anthony Devane in 1982 while working at Sterling-Winthrop pharmaceuticals. The patent claims were filed on January 18, 1980, and granted on July 27, 1988 (US Patent 4646957). A later study showed that the dextrorotatory enantiomer of delta 8 THC was more potent than the levorotatory enantiomer and that racemic delta 8 THC while providing analgesic effects, would also cause dysphoric reactions due to its psychoactive effects.
Delta-8 THC is one of four stereoisomers of tetrahydrocannabinol (THC), the other three being THCA, CBDA and CBCA. It has been shown by X-ray crystallography analysis at 2.05 Å resolution. Studies have been done to determine how synthetic cannabinoids such as JWH-018 bind specifically to the CB1 receptor as an agonist with minimal activity towards CB2. In a study done in 2009, it was found that two hydrogen bonds were responsible for recognizing the aromatic portion of cannabinoid receptor 1 (CB1). Buy Delta 8 THC Flower Online, and it will be delivered to your home.
A combination of three hydrogen bonds and Van der Waals interactions were needed to bind anandamide, also an agonist at CB1. When compared with the average synthetic cannabinoid binding in this way it was found that JWH-018 had a difference in an activity that can be attributed to the lack of these hydrogen bonds and Van der Waals interactions. This finding is backed up by another study done with AM6527 which showed no significant SR-144302 like properties when tested at CB1. It’s important to note that most cannabinoids such as THC and synthetic cannabinoids anandamide have both SR-144302 like and JWH-018 like properties so it makes sense for them to share a structure although they function quite differently.
Delta-8 THC has local anesthetic activity similar to that of procaine, although much less potent. Delta-8 THC is an agonist at CB1 and CB2 receptors with low nanomolar affinity for both. The receptor subtype selectivity was determined by evaluating the inhibition constant (Ki) values at the cannabinoid receptors using human embryonic kidney cell line expressing cDNA corresponding to CB1 or CB2 receptors. The Highest Ki value was observed at the CB2 receptor. By applying structure-activity relationship, it can be concluded that modification on C8 position is more suitable than on C7, which is planar in delta-8 THCs. It should be noted that neither enantiomers nor diastereomeric derivatives of this compound have been tested at the CB1 and CB2 receptors to determine whether they might show even higher affinities.